235 related articles for article (PubMed ID: 33657135)
1. A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2.
Yao H; Cai H; Li T; Zhou B; Qin W; Lavillette D; Li D
PLoS Pathog; 2021 Mar; 17(3):e1009328. PubMed ID: 33657135
[TBL] [Abstract][Full Text] [Related]
2. A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection.
Li T; Cai H; Yao H; Zhou B; Zhang N; van Vlissingen MF; Kuiken T; Han W; GeurtsvanKessel CH; Gong Y; Zhao Y; Shen Q; Qin W; Tian XX; Peng C; Lai Y; Wang Y; Hutter CAJ; Kuo SM; Bao J; Liu C; Wang Y; Richard AS; Raoul H; Lan J; Seeger MA; Cong Y; Rockx B; Wong G; Bi Y; Lavillette D; Li D
Nat Commun; 2021 Jul; 12(1):4635. PubMed ID: 34330908
[TBL] [Abstract][Full Text] [Related]
3. Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2.
Huo J; Le Bas A; Ruza RR; Duyvesteyn HME; Mikolajek H; Malinauskas T; Tan TK; Rijal P; Dumoux M; Ward PN; Ren J; Zhou D; Harrison PJ; Weckener M; Clare DK; Vogirala VK; Radecke J; Moynié L; Zhao Y; Gilbert-Jaramillo J; Knight ML; Tree JA; Buttigieg KR; Coombes N; Elmore MJ; Carroll MW; Carrique L; Shah PNM; James W; Townsend AR; Stuart DI; Owens RJ; Naismith JH
Nat Struct Mol Biol; 2020 Sep; 27(9):846-854. PubMed ID: 32661423
[TBL] [Abstract][Full Text] [Related]
4. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
Yang J; Zhang Z; Yang F; Zhang H; Wu H; Zhu F; Xue W
Chem Biol Drug Des; 2021 Jul; 98(1):1-18. PubMed ID: 33894099
[TBL] [Abstract][Full Text] [Related]
5. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2.
Xiang Y; Nambulli S; Xiao Z; Liu H; Sang Z; Duprex WP; Schneidman-Duhovny D; Zhang C; Shi Y
Science; 2020 Dec; 370(6523):1479-1484. PubMed ID: 33154108
[TBL] [Abstract][Full Text] [Related]
6. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
[TBL] [Abstract][Full Text] [Related]
7. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
8. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
9. A non-ACE2 competing human single-domain antibody confers broad neutralization against SARS-CoV-2 and circulating variants.
Yang Z; Wang Y; Jin Y; Zhu Y; Wu Y; Li C; Kong Y; Song W; Tian X; Zhan W; Huang A; Zhou S; Xia S; Tian X; Peng C; Chen C; Shi Y; Hu G; Du S; Wang Y; Xie Y; Jiang S; Lu L; Sun L; Song Y; Ying T
Signal Transduct Target Ther; 2021 Nov; 6(1):378. PubMed ID: 34732694
[TBL] [Abstract][Full Text] [Related]
10. Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2.
Bracken CJ; Lim SA; Solomon P; Rettko NJ; Nguyen DP; Zha BS; Schaefer K; Byrnes JR; Zhou J; Lui I; Liu J; Pance K; ; Zhou XX; Leung KK; Wells JA
Nat Chem Biol; 2021 Jan; 17(1):113-121. PubMed ID: 33082574
[TBL] [Abstract][Full Text] [Related]
11. An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike.
Schoof M; Faust B; Saunders RA; Sangwan S; Rezelj V; Hoppe N; Boone M; Billesbølle CB; Puchades C; Azumaya CM; Kratochvil HT; Zimanyi M; Deshpande I; Liang J; Dickinson S; Nguyen HC; Chio CM; Merz GE; Thompson MC; Diwanji D; Schaefer K; Anand AA; Dobzinski N; Zha BS; Simoneau CR; Leon K; White KM; Chio US; Gupta M; Jin M; Li F; Liu Y; Zhang K; Bulkley D; Sun M; Smith AM; Rizo AN; Moss F; Brilot AF; Pourmal S; Trenker R; Pospiech T; Gupta S; Barsi-Rhyne B; Belyy V; Barile-Hill AW; Nock S; Liu Y; Krogan NJ; Ralston CY; Swaney DL; García-Sastre A; Ott M; Vignuzzi M; ; Walter P; Manglik A
Science; 2020 Dec; 370(6523):1473-1479. PubMed ID: 33154106
[TBL] [Abstract][Full Text] [Related]
12. Screening and optimization of shark nanobodies against SARS-CoV-2 spike RBD.
Liu X; Wang Y; Sun L; Xiao G; Hou N; Chen J; Wang W; Xu X; Gu Y
Antiviral Res; 2024 Jun; 226():105898. PubMed ID: 38692413
[TBL] [Abstract][Full Text] [Related]
13. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.
Lu Q; Zhang Z; Li H; Zhong K; Zhao Q; Wang Z; Wu Z; Yang D; Sun S; Yang N; Zheng M; Chen Q; Long C; Guo W; Yang H; Nie C; Tong A
J Nanobiotechnology; 2021 Jan; 19(1):33. PubMed ID: 33514385
[TBL] [Abstract][Full Text] [Related]
14. Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody.
Valenzuela Nieto G; Jara R; Watterson D; Modhiran N; Amarilla AA; Himelreichs J; Khromykh AA; Salinas-Rebolledo C; Pinto T; Cheuquemilla Y; Margolles Y; López González Del Rey N; Miranda-Chacon Z; Cuevas A; Berking A; Deride C; González-Moraga S; Mancilla H; Maturana D; Langer A; Toledo JP; Müller A; Uberti B; Krall P; Ehrenfeld P; Blesa J; Chana-Cuevas P; Rehren G; Schwefel D; Fernandez LÁ; Rojas-Fernandez A
Sci Rep; 2021 Feb; 11(1):3318. PubMed ID: 33558635
[TBL] [Abstract][Full Text] [Related]
15. Enhanced elicitation of potent neutralizing antibodies by the SARS-CoV-2 spike receptor binding domain Fc fusion protein in mice.
Liu X; Drelich A; Li W; Chen C; Sun Z; Shi M; Adams C; Mellors JW; Tseng CT; Dimitrov DS
Vaccine; 2020 Oct; 38(46):7205-7212. PubMed ID: 33010978
[TBL] [Abstract][Full Text] [Related]
16. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
[TBL] [Abstract][Full Text] [Related]
17. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice.
Pymm P; Adair A; Chan LJ; Cooney JP; Mordant FL; Allison CC; Lopez E; Haycroft ER; O'Neill MT; Tan LL; Dietrich MH; Drew D; Doerflinger M; Dengler MA; Scott NE; Wheatley AK; Gherardin NA; Venugopal H; Cromer D; Davenport MP; Pickering R; Godfrey DI; Purcell DFJ; Kent SJ; Chung AW; Subbarao K; Pellegrini M; Glukhova A; Tham WH
Proc Natl Acad Sci U S A; 2021 May; 118(19):. PubMed ID: 33893175
[TBL] [Abstract][Full Text] [Related]
18. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape.
Koenig PA; Das H; Liu H; Kümmerer BM; Gohr FN; Jenster LM; Schiffelers LDJ; Tesfamariam YM; Uchima M; Wuerth JD; Gatterdam K; Ruetalo N; Christensen MH; Fandrey CI; Normann S; Tödtmann JMP; Pritzl S; Hanke L; Boos J; Yuan M; Zhu X; Schmid-Burgk JL; Kato H; Schindler M; Wilson IA; Geyer M; Ludwig KU; Hällberg BM; Wu NC; Schmidt FI
Science; 2021 Feb; 371(6530):. PubMed ID: 33436526
[TBL] [Abstract][Full Text] [Related]
19. Enhanced potency of an IgM-like nanobody targeting conserved epitope in SARS-CoV-2 spike N-terminal domain.
Liu B; Liu H; Han P; Wang X; Wang C; Yan X; Lei W; Xu K; Zhou J; Qi J; Fan R; Wu G; Tian WX; Gao GF; Wang Q
Signal Transduct Target Ther; 2024 May; 9(1):131. PubMed ID: 38740785
[TBL] [Abstract][Full Text] [Related]
20. Structures of synthetic nanobody-SARS-CoV-2 receptor-binding domain complexes reveal distinct sites of interaction.
Ahmad J; Jiang J; Boyd LF; Zeher A; Huang R; Xia D; Natarajan K; Margulies DH
J Biol Chem; 2021 Oct; 297(4):101202. PubMed ID: 34537245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
